Curegenix Inc. Report issue

For profit Phase 1
Founded: Guangzhou China (2009)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2016
NCT02675946
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Curegenix Inc. | Guangzhou Curegenix Co. Ltd.

Active Ingredients

Drugs in Phase 1 Trials (1)

cgx1321 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Ductal (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Digestive System Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 1)

Gastrointestinal Neoplasms (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1